Skip to content

Safety and Performance of the OTTAVA Robotic System

EDS-2022-01: Safety and Performance of the OTTAVA™ Robotic System: A Prospective, Multi-Center Evaluation (FORTE)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06709261
Acronym
FORTE
Enrollment
32
Registered
2024-11-29
Start date
2025-02-05
Completion date
2025-10-20
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

This study assesses safety and performance of the OTTAVA Robotic System, through 30 days postoperative, in subjects undergoing robotic-assisted Roux-en-Y Gastric Bypass (RYGB) procedure.

Interventions

Procedure with the OTTAVA Robotic System

Sponsors

Auris Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Criteria for Inclusion: 1. Willing and able to provide informed consent; 2. Scheduled for an elective primary RYGB surgical procedure; 3. American Society of Anesthesiologists classification ≤ ASA III; 4. Body habitus such that the procedure can be safely completed with OTTAVA Robotic System; 5. Body weight \<500 lb (227 kg); 6. Patient presenting with class 2 or 3 obesity (BMI ≥ 35), regardless of comorbidities, or obesity with health risk satisfying 2022 ASMBS/IFSO indications for bariatric surgery; and 7. A minimum of 21 years of age (at time of consent). Criteria for Exclusion: 1. Surgeon determination that there is a medical condition, that makes surgery too risky, including intraoperative finding; 2. Concomitant surgical procedure including cholecystectomy (hiatal hernia repair up to 5 cm and adhesiolysis allowed); 3. Upper abdominal surgery within two years prior to enrollment (prior laparoscopic cholecystectomy allowed); 4. Evidence of hiatal hernia \>5 cm (preoperative/intraoperative); 5. Enrolled in another investigational study that may confound the results of this study; 6. Emergency surgery; 7. Active pregnancy; or 8. Subject from a vulnerable population, including anyone unable to adequately provide informed consent.

Design outcomes

Primary

MeasureTime frame
Procedure completion without conversion to open surgeryProcedure day
Occurrence of intraoperative and postoperative device- or procedure-related complicationsThrough 30 days post-procedure

Secondary

MeasureTime frame
Occurrence of all adverse eventsThrough 30 days post-procedure
Total operative timeProcedure day
Estimated blood lossProcedure day
Occurrence of blood transfusionProcedure day
Device malfunction detailsProcedure day
Length of hospital stayHospital stay, assessed up to 30 days
Hospital readmissionThrough 30 days
ReoperationThrough 30 days
Anastomotic leakThrough 30 days
Anastomotic strictureThrough 30 days
MortalityThrough 30 days

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORErik Wilson, MD

Memorial Hermann Texas Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026